nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—ABCB1—esophageal cancer	0.235	1	CbGaD
Dabrafenib—SLCO1B3—Methotrexate—esophageal cancer	0.087	0.203	CbGbCtD
Dabrafenib—ABCG2—Carboplatin—esophageal cancer	0.0726	0.169	CbGbCtD
Dabrafenib—ABCG2—Cisplatin—esophageal cancer	0.062	0.145	CbGbCtD
Dabrafenib—SLCO1B1—Methotrexate—esophageal cancer	0.0507	0.118	CbGbCtD
Dabrafenib—SLC22A8—Methotrexate—esophageal cancer	0.0468	0.109	CbGbCtD
Dabrafenib—ABCG2—Methotrexate—esophageal cancer	0.0403	0.0939	CbGbCtD
Dabrafenib—SLC22A6—Methotrexate—esophageal cancer	0.0326	0.076	CbGbCtD
Dabrafenib—ABCB1—Cisplatin—esophageal cancer	0.0224	0.0521	CbGbCtD
Dabrafenib—ABCB1—Methotrexate—esophageal cancer	0.0145	0.0339	CbGbCtD
Dabrafenib—Actinic keratosis—Capecitabine—esophageal cancer	0.00848	0.0691	CcSEcCtD
Dabrafenib—Ocular toxicity—Cisplatin—esophageal cancer	0.00708	0.0577	CcSEcCtD
Dabrafenib—Seborrhoeic keratosis—Capecitabine—esophageal cancer	0.00673	0.0549	CcSEcCtD
Dabrafenib—NEK11—lung—esophageal cancer	0.00356	0.115	CbGeAlD
Dabrafenib—Paronychia—Methotrexate—esophageal cancer	0.00303	0.0247	CcSEcCtD
Dabrafenib—Lymphoedema—Capecitabine—esophageal cancer	0.00289	0.0236	CcSEcCtD
Dabrafenib—Blindness transient—Methotrexate—esophageal cancer	0.00288	0.0235	CcSEcCtD
Dabrafenib—Skin lesion—Capecitabine—esophageal cancer	0.00271	0.0221	CcSEcCtD
Dabrafenib—Hyperkeratosis—Capecitabine—esophageal cancer	0.00247	0.0201	CcSEcCtD
Dabrafenib—NEK11—lymph node—esophageal cancer	0.00244	0.0784	CbGeAlD
Dabrafenib—RAF1—neck—esophageal cancer	0.00243	0.0781	CbGeAlD
Dabrafenib—Abdominal pain lower—Capecitabine—esophageal cancer	0.00222	0.0181	CcSEcCtD
Dabrafenib—SIK1—bronchus—esophageal cancer	0.00204	0.0657	CbGeAlD
Dabrafenib—LIMK1—lymph node—esophageal cancer	0.00174	0.0561	CbGeAlD
Dabrafenib—Rash macular—Capecitabine—esophageal cancer	0.00172	0.014	CcSEcCtD
Dabrafenib—RAF1—epithelium—esophageal cancer	0.00165	0.0531	CbGeAlD
Dabrafenib—Hypophosphataemia—Cisplatin—esophageal cancer	0.00165	0.0134	CcSEcCtD
Dabrafenib—RAF1—bronchus—esophageal cancer	0.00163	0.0523	CbGeAlD
Dabrafenib—RAF1—smooth muscle tissue—esophageal cancer	0.00159	0.0512	CbGeAlD
Dabrafenib—BRAF—lung—esophageal cancer	0.00157	0.0507	CbGeAlD
Dabrafenib—Prurigo—Capecitabine—esophageal cancer	0.00153	0.0125	CcSEcCtD
Dabrafenib—RAF1—trachea—esophageal cancer	0.00146	0.047	CbGeAlD
Dabrafenib—Cardiomyopathy—Capecitabine—esophageal cancer	0.00138	0.0113	CcSEcCtD
Dabrafenib—Lymphopenia—Capecitabine—esophageal cancer	0.00138	0.0113	CcSEcCtD
Dabrafenib—SLCO1B3—lung—esophageal cancer	0.00136	0.0437	CbGeAlD
Dabrafenib—SIK1—lung—esophageal cancer	0.00132	0.0424	CbGeAlD
Dabrafenib—Night sweats—Capecitabine—esophageal cancer	0.00131	0.0107	CcSEcCtD
Dabrafenib—RAF1—digestive system—esophageal cancer	0.00126	0.0404	CbGeAlD
Dabrafenib—Infection—Carboplatin—esophageal cancer	0.00116	0.00944	CcSEcCtD
Dabrafenib—Hypomagnesaemia—Capecitabine—esophageal cancer	0.00111	0.00906	CcSEcCtD
Dabrafenib—Nephropathy—Methotrexate—esophageal cancer	0.0011	0.009	CcSEcCtD
Dabrafenib—BRAF—lymph node—esophageal cancer	0.00108	0.0347	CbGeAlD
Dabrafenib—Cellulitis—Cisplatin—esophageal cancer	0.00105	0.00859	CcSEcCtD
Dabrafenib—RAF1—lung—esophageal cancer	0.00105	0.0338	CbGeAlD
Dabrafenib—Hypercalcaemia—Capecitabine—esophageal cancer	0.00102	0.00829	CcSEcCtD
Dabrafenib—Azotaemia—Methotrexate—esophageal cancer	0.000987	0.00804	CcSEcCtD
Dabrafenib—Vaginal haemorrhage—Capecitabine—esophageal cancer	0.000954	0.00778	CcSEcCtD
Dabrafenib—Hyperkalaemia—Cisplatin—esophageal cancer	0.000941	0.00767	CcSEcCtD
Dabrafenib—SLCO1B1—digestive system—esophageal cancer	0.00094	0.0302	CbGeAlD
Dabrafenib—Rash erythematous—Capecitabine—esophageal cancer	0.000922	0.00752	CcSEcCtD
Dabrafenib—Body temperature increased—Carboplatin—esophageal cancer	0.000921	0.00751	CcSEcCtD
Dabrafenib—SIK1—lymph node—esophageal cancer	0.000901	0.029	CbGeAlD
Dabrafenib—Rigors—Capecitabine—esophageal cancer	0.000865	0.00705	CcSEcCtD
Dabrafenib—Polyp—Methotrexate—esophageal cancer	0.000864	0.00704	CcSEcCtD
Dabrafenib—Folliculitis—Methotrexate—esophageal cancer	0.000836	0.00682	CcSEcCtD
Dabrafenib—Cyst—Methotrexate—esophageal cancer	0.000787	0.00641	CcSEcCtD
Dabrafenib—Cellulitis—Capecitabine—esophageal cancer	0.000777	0.00633	CcSEcCtD
Dabrafenib—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.000777	0.00633	CcSEcCtD
Dabrafenib—Oropharyngeal pain—Capecitabine—esophageal cancer	0.000777	0.00633	CcSEcCtD
Dabrafenib—Hypocalcaemia—Capecitabine—esophageal cancer	0.000772	0.00629	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Cisplatin—esophageal cancer	0.000767	0.00625	CcSEcCtD
Dabrafenib—Renal failure acute—Cisplatin—esophageal cancer	0.000753	0.00614	CcSEcCtD
Dabrafenib—RAF1—lymph node—esophageal cancer	0.000718	0.0231	CbGeAlD
Dabrafenib—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.000706	0.00576	CcSEcCtD
Dabrafenib—Hyponatraemia—Cisplatin—esophageal cancer	0.000698	0.00569	CcSEcCtD
Dabrafenib—Influenza like illness—Capecitabine—esophageal cancer	0.000686	0.00559	CcSEcCtD
Dabrafenib—Blood creatinine increased—Cisplatin—esophageal cancer	0.000652	0.00531	CcSEcCtD
Dabrafenib—Dehydration—Cisplatin—esophageal cancer	0.000647	0.00527	CcSEcCtD
Dabrafenib—Neoplasm—Capecitabine—esophageal cancer	0.000639	0.00521	CcSEcCtD
Dabrafenib—Hypokalaemia—Cisplatin—esophageal cancer	0.000633	0.00516	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000626	0.00511	CcSEcCtD
Dabrafenib—Nasopharyngitis—Cisplatin—esophageal cancer	0.000622	0.00507	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.000589	0.0048	CcSEcCtD
Dabrafenib—Pancreatitis—Cisplatin—esophageal cancer	0.000589	0.0048	CcSEcCtD
Dabrafenib—Bone disorder—Methotrexate—esophageal cancer	0.000582	0.00474	CcSEcCtD
Dabrafenib—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.000578	0.00471	CcSEcCtD
Dabrafenib—Abdominal discomfort—Cisplatin—esophageal cancer	0.000576	0.0047	CcSEcCtD
Dabrafenib—Renal failure acute—Capecitabine—esophageal cancer	0.000555	0.00453	CcSEcCtD
Dabrafenib—Dermatitis bullous—Capecitabine—esophageal cancer	0.000536	0.00437	CcSEcCtD
Dabrafenib—Renal failure—Cisplatin—esophageal cancer	0.000527	0.00429	CcSEcCtD
Dabrafenib—Stomatitis—Cisplatin—esophageal cancer	0.000522	0.00426	CcSEcCtD
Dabrafenib—Hyponatraemia—Capecitabine—esophageal cancer	0.000515	0.0042	CcSEcCtD
Dabrafenib—Pain in extremity—Capecitabine—esophageal cancer	0.000513	0.00418	CcSEcCtD
Dabrafenib—Blood creatinine increased—Capecitabine—esophageal cancer	0.00048	0.00392	CcSEcCtD
Dabrafenib—Dehydration—Capecitabine—esophageal cancer	0.000477	0.00389	CcSEcCtD
Dabrafenib—Neoplasm—Methotrexate—esophageal cancer	0.000475	0.00387	CcSEcCtD
Dabrafenib—Urinary tract disorder—Cisplatin—esophageal cancer	0.000475	0.00387	CcSEcCtD
Dabrafenib—Connective tissue disorder—Cisplatin—esophageal cancer	0.000473	0.00385	CcSEcCtD
Dabrafenib—Urethral disorder—Cisplatin—esophageal cancer	0.000472	0.00384	CcSEcCtD
Dabrafenib—Dry skin—Capecitabine—esophageal cancer	0.00047	0.00383	CcSEcCtD
Dabrafenib—Abdominal pain upper—Capecitabine—esophageal cancer	0.000468	0.00382	CcSEcCtD
Dabrafenib—Hypokalaemia—Capecitabine—esophageal cancer	0.000467	0.0038	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000462	0.00376	CcSEcCtD
Dabrafenib—Nasopharyngitis—Capecitabine—esophageal cancer	0.000458	0.00374	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000452	0.00369	CcSEcCtD
Dabrafenib—Eye disorder—Cisplatin—esophageal cancer	0.00045	0.00367	CcSEcCtD
Dabrafenib—Immune system disorder—Cisplatin—esophageal cancer	0.000435	0.00354	CcSEcCtD
Dabrafenib—ABCG2—lung—esophageal cancer	0.000434	0.014	CbGeAlD
Dabrafenib—Mediastinal disorder—Cisplatin—esophageal cancer	0.000434	0.00353	CcSEcCtD
Dabrafenib—Arrhythmia—Cisplatin—esophageal cancer	0.00043	0.0035	CcSEcCtD
Dabrafenib—Alopecia—Cisplatin—esophageal cancer	0.000425	0.00347	CcSEcCtD
Dabrafenib—Abdominal discomfort—Capecitabine—esophageal cancer	0.000425	0.00346	CcSEcCtD
Dabrafenib—Erythema—Cisplatin—esophageal cancer	0.000419	0.00341	CcSEcCtD
Dabrafenib—Malnutrition—Cisplatin—esophageal cancer	0.000419	0.00341	CcSEcCtD
Dabrafenib—Neutropenia—Capecitabine—esophageal cancer	0.000414	0.00338	CcSEcCtD
Dabrafenib—Renal failure acute—Methotrexate—esophageal cancer	0.000413	0.00337	CcSEcCtD
Dabrafenib—Muscle spasms—Cisplatin—esophageal cancer	0.000403	0.00328	CcSEcCtD
Dabrafenib—Hyperglycaemia—Capecitabine—esophageal cancer	0.0004	0.00326	CcSEcCtD
Dabrafenib—Infestation—Capecitabine—esophageal cancer	0.000395	0.00322	CcSEcCtD
Dabrafenib—Infestation NOS—Capecitabine—esophageal cancer	0.000395	0.00322	CcSEcCtD
Dabrafenib—Vision blurred—Cisplatin—esophageal cancer	0.000395	0.00322	CcSEcCtD
Dabrafenib—Renal failure—Capecitabine—esophageal cancer	0.000388	0.00317	CcSEcCtD
Dabrafenib—Anaemia—Cisplatin—esophageal cancer	0.000387	0.00316	CcSEcCtD
Dabrafenib—Stomatitis—Capecitabine—esophageal cancer	0.000385	0.00314	CcSEcCtD
Dabrafenib—Urinary tract infection—Capecitabine—esophageal cancer	0.000384	0.00313	CcSEcCtD
Dabrafenib—Haematuria—Capecitabine—esophageal cancer	0.000377	0.00307	CcSEcCtD
Dabrafenib—Leukopenia—Cisplatin—esophageal cancer	0.000375	0.00306	CcSEcCtD
Dabrafenib—Epistaxis—Capecitabine—esophageal cancer	0.000373	0.00304	CcSEcCtD
Dabrafenib—CYP3A4—digestive system—esophageal cancer	0.000362	0.0116	CbGeAlD
Dabrafenib—Myalgia—Cisplatin—esophageal cancer	0.000357	0.00291	CcSEcCtD
Dabrafenib—Haemoglobin—Capecitabine—esophageal cancer	0.000356	0.00291	CcSEcCtD
Dabrafenib—Haemorrhage—Capecitabine—esophageal cancer	0.000355	0.00289	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000354	0.00289	CcSEcCtD
Dabrafenib—Urinary tract disorder—Capecitabine—esophageal cancer	0.00035	0.00286	CcSEcCtD
Dabrafenib—Oedema peripheral—Capecitabine—esophageal cancer	0.000349	0.00285	CcSEcCtD
Dabrafenib—Connective tissue disorder—Capecitabine—esophageal cancer	0.000349	0.00284	CcSEcCtD
Dabrafenib—Urethral disorder—Capecitabine—esophageal cancer	0.000348	0.00283	CcSEcCtD
Dabrafenib—Oedema—Cisplatin—esophageal cancer	0.000342	0.00279	CcSEcCtD
Dabrafenib—Infection—Cisplatin—esophageal cancer	0.00034	0.00277	CcSEcCtD
Dabrafenib—ABCB1—epithelium—esophageal cancer	0.000337	0.0108	CbGeAlD
Dabrafenib—Nervous system disorder—Cisplatin—esophageal cancer	0.000335	0.00273	CcSEcCtD
Dabrafenib—Thrombocytopenia—Cisplatin—esophageal cancer	0.000335	0.00273	CcSEcCtD
Dabrafenib—Skin disorder—Cisplatin—esophageal cancer	0.000332	0.00271	CcSEcCtD
Dabrafenib—Eye disorder—Capecitabine—esophageal cancer	0.000331	0.0027	CcSEcCtD
Dabrafenib—Hyperhidrosis—Cisplatin—esophageal cancer	0.00033	0.00269	CcSEcCtD
Dabrafenib—Pancreatitis—Methotrexate—esophageal cancer	0.000323	0.00264	CcSEcCtD
Dabrafenib—Angiopathy—Capecitabine—esophageal cancer	0.000322	0.00262	CcSEcCtD
Dabrafenib—Immune system disorder—Capecitabine—esophageal cancer	0.00032	0.00261	CcSEcCtD
Dabrafenib—Mediastinal disorder—Capecitabine—esophageal cancer	0.00032	0.00261	CcSEcCtD
Dabrafenib—Hypotension—Cisplatin—esophageal cancer	0.000319	0.0026	CcSEcCtD
Dabrafenib—Chills—Capecitabine—esophageal cancer	0.000318	0.00259	CcSEcCtD
Dabrafenib—Arrhythmia—Capecitabine—esophageal cancer	0.000317	0.00258	CcSEcCtD
Dabrafenib—Abdominal discomfort—Methotrexate—esophageal cancer	0.000316	0.00258	CcSEcCtD
Dabrafenib—Alopecia—Capecitabine—esophageal cancer	0.000313	0.00255	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000311	0.00254	CcSEcCtD
Dabrafenib—Mental disorder—Capecitabine—esophageal cancer	0.000311	0.00253	CcSEcCtD
Dabrafenib—Malnutrition—Capecitabine—esophageal cancer	0.000309	0.00252	CcSEcCtD
Dabrafenib—Erythema—Capecitabine—esophageal cancer	0.000309	0.00252	CcSEcCtD
Dabrafenib—Neutropenia—Methotrexate—esophageal cancer	0.000308	0.00251	CcSEcCtD
Dabrafenib—Back pain—Capecitabine—esophageal cancer	0.000299	0.00243	CcSEcCtD
Dabrafenib—ABCB1—trachea—esophageal cancer	0.000298	0.00958	CbGeAlD
Dabrafenib—Decreased appetite—Cisplatin—esophageal cancer	0.000297	0.00242	CcSEcCtD
Dabrafenib—Muscle spasms—Capecitabine—esophageal cancer	0.000297	0.00242	CcSEcCtD
Dabrafenib—ABCG2—lymph node—esophageal cancer	0.000297	0.00955	CbGeAlD
Dabrafenib—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000295	0.00241	CcSEcCtD
Dabrafenib—Infestation—Methotrexate—esophageal cancer	0.000294	0.0024	CcSEcCtD
Dabrafenib—Infestation NOS—Methotrexate—esophageal cancer	0.000294	0.0024	CcSEcCtD
Dabrafenib—Vision blurred—Capecitabine—esophageal cancer	0.000291	0.00237	CcSEcCtD
Dabrafenib—Renal failure—Methotrexate—esophageal cancer	0.000289	0.00236	CcSEcCtD
Dabrafenib—Stomatitis—Methotrexate—esophageal cancer	0.000287	0.00234	CcSEcCtD
Dabrafenib—Anaemia—Capecitabine—esophageal cancer	0.000285	0.00233	CcSEcCtD
Dabrafenib—Haematuria—Methotrexate—esophageal cancer	0.00028	0.00229	CcSEcCtD
Dabrafenib—Epistaxis—Methotrexate—esophageal cancer	0.000277	0.00226	CcSEcCtD
Dabrafenib—Leukopenia—Capecitabine—esophageal cancer	0.000276	0.00225	CcSEcCtD
Dabrafenib—Body temperature increased—Cisplatin—esophageal cancer	0.00027	0.0022	CcSEcCtD
Dabrafenib—Cough—Capecitabine—esophageal cancer	0.000269	0.0022	CcSEcCtD
Dabrafenib—Hypertension—Capecitabine—esophageal cancer	0.000267	0.00217	CcSEcCtD
Dabrafenib—Haemoglobin—Methotrexate—esophageal cancer	0.000265	0.00216	CcSEcCtD
Dabrafenib—Haemorrhage—Methotrexate—esophageal cancer	0.000264	0.00215	CcSEcCtD
Dabrafenib—Arthralgia—Capecitabine—esophageal cancer	0.000263	0.00214	CcSEcCtD
Dabrafenib—Myalgia—Capecitabine—esophageal cancer	0.000263	0.00214	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000261	0.00213	CcSEcCtD
Dabrafenib—Urinary tract disorder—Methotrexate—esophageal cancer	0.000261	0.00213	CcSEcCtD
Dabrafenib—Urethral disorder—Methotrexate—esophageal cancer	0.000259	0.00211	CcSEcCtD
Dabrafenib—Dry mouth—Capecitabine—esophageal cancer	0.000257	0.0021	CcSEcCtD
Dabrafenib—ABCB1—digestive system—esophageal cancer	0.000256	0.00825	CbGeAlD
Dabrafenib—Oedema—Capecitabine—esophageal cancer	0.000252	0.00205	CcSEcCtD
Dabrafenib—Hypersensitivity—Cisplatin—esophageal cancer	0.000252	0.00205	CcSEcCtD
Dabrafenib—Infection—Capecitabine—esophageal cancer	0.00025	0.00204	CcSEcCtD
Dabrafenib—Nervous system disorder—Capecitabine—esophageal cancer	0.000247	0.00201	CcSEcCtD
Dabrafenib—Eye disorder—Methotrexate—esophageal cancer	0.000247	0.00201	CcSEcCtD
Dabrafenib—Thrombocytopenia—Capecitabine—esophageal cancer	0.000247	0.00201	CcSEcCtD
Dabrafenib—Asthenia—Cisplatin—esophageal cancer	0.000245	0.002	CcSEcCtD
Dabrafenib—Skin disorder—Capecitabine—esophageal cancer	0.000245	0.002	CcSEcCtD
Dabrafenib—Hyperhidrosis—Capecitabine—esophageal cancer	0.000244	0.00199	CcSEcCtD
Dabrafenib—Angiopathy—Methotrexate—esophageal cancer	0.00024	0.00195	CcSEcCtD
Dabrafenib—Immune system disorder—Methotrexate—esophageal cancer	0.000238	0.00194	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methotrexate—esophageal cancer	0.000238	0.00194	CcSEcCtD
Dabrafenib—Chills—Methotrexate—esophageal cancer	0.000237	0.00193	CcSEcCtD
Dabrafenib—Hypotension—Capecitabine—esophageal cancer	0.000235	0.00192	CcSEcCtD
Dabrafenib—Diarrhoea—Cisplatin—esophageal cancer	0.000234	0.00191	CcSEcCtD
Dabrafenib—Alopecia—Methotrexate—esophageal cancer	0.000233	0.0019	CcSEcCtD
Dabrafenib—Mental disorder—Methotrexate—esophageal cancer	0.000231	0.00189	CcSEcCtD
Dabrafenib—Erythema—Methotrexate—esophageal cancer	0.00023	0.00187	CcSEcCtD
Dabrafenib—Malnutrition—Methotrexate—esophageal cancer	0.00023	0.00187	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00023	0.00187	CcSEcCtD
Dabrafenib—Insomnia—Capecitabine—esophageal cancer	0.000228	0.00186	CcSEcCtD
Dabrafenib—Back pain—Methotrexate—esophageal cancer	0.000222	0.00181	CcSEcCtD
Dabrafenib—Decreased appetite—Capecitabine—esophageal cancer	0.000219	0.00179	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000218	0.00177	CcSEcCtD
Dabrafenib—Vomiting—Cisplatin—esophageal cancer	0.000217	0.00177	CcSEcCtD
Dabrafenib—Fatigue—Capecitabine—esophageal cancer	0.000217	0.00177	CcSEcCtD
Dabrafenib—Vision blurred—Methotrexate—esophageal cancer	0.000217	0.00177	CcSEcCtD
Dabrafenib—Rash—Cisplatin—esophageal cancer	0.000216	0.00176	CcSEcCtD
Dabrafenib—Constipation—Capecitabine—esophageal cancer	0.000215	0.00176	CcSEcCtD
Dabrafenib—Dermatitis—Cisplatin—esophageal cancer	0.000215	0.00176	CcSEcCtD
Dabrafenib—ABCB1—lung—esophageal cancer	0.000214	0.00689	CbGeAlD
Dabrafenib—Anaemia—Methotrexate—esophageal cancer	0.000212	0.00173	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000206	0.00168	CcSEcCtD
Dabrafenib—Leukopenia—Methotrexate—esophageal cancer	0.000206	0.00168	CcSEcCtD
Dabrafenib—Nausea—Cisplatin—esophageal cancer	0.000203	0.00166	CcSEcCtD
Dabrafenib—Cough—Methotrexate—esophageal cancer	0.000201	0.00163	CcSEcCtD
Dabrafenib—Body temperature increased—Capecitabine—esophageal cancer	0.000199	0.00162	CcSEcCtD
Dabrafenib—Abdominal pain—Capecitabine—esophageal cancer	0.000199	0.00162	CcSEcCtD
Dabrafenib—Arthralgia—Methotrexate—esophageal cancer	0.000196	0.0016	CcSEcCtD
Dabrafenib—Myalgia—Methotrexate—esophageal cancer	0.000196	0.0016	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000194	0.00158	CcSEcCtD
Dabrafenib—Infection—Methotrexate—esophageal cancer	0.000186	0.00152	CcSEcCtD
Dabrafenib—Hypersensitivity—Capecitabine—esophageal cancer	0.000186	0.00151	CcSEcCtD
Dabrafenib—Nervous system disorder—Methotrexate—esophageal cancer	0.000184	0.0015	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methotrexate—esophageal cancer	0.000184	0.0015	CcSEcCtD
Dabrafenib—Skin disorder—Methotrexate—esophageal cancer	0.000182	0.00149	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methotrexate—esophageal cancer	0.000181	0.00148	CcSEcCtD
Dabrafenib—Asthenia—Capecitabine—esophageal cancer	0.000181	0.00147	CcSEcCtD
Dabrafenib—Pruritus—Capecitabine—esophageal cancer	0.000178	0.00145	CcSEcCtD
Dabrafenib—Hypotension—Methotrexate—esophageal cancer	0.000175	0.00143	CcSEcCtD
Dabrafenib—Diarrhoea—Capecitabine—esophageal cancer	0.000172	0.00141	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000171	0.00139	CcSEcCtD
Dabrafenib—Insomnia—Methotrexate—esophageal cancer	0.00017	0.00138	CcSEcCtD
Dabrafenib—Dizziness—Capecitabine—esophageal cancer	0.000167	0.00136	CcSEcCtD
Dabrafenib—Decreased appetite—Methotrexate—esophageal cancer	0.000163	0.00133	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000162	0.00132	CcSEcCtD
Dabrafenib—Fatigue—Methotrexate—esophageal cancer	0.000162	0.00132	CcSEcCtD
Dabrafenib—Vomiting—Capecitabine—esophageal cancer	0.00016	0.00131	CcSEcCtD
Dabrafenib—Rash—Capecitabine—esophageal cancer	0.000159	0.0013	CcSEcCtD
Dabrafenib—Dermatitis—Capecitabine—esophageal cancer	0.000159	0.00129	CcSEcCtD
Dabrafenib—Headache—Capecitabine—esophageal cancer	0.000158	0.00129	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000153	0.00125	CcSEcCtD
Dabrafenib—Nausea—Capecitabine—esophageal cancer	0.00015	0.00122	CcSEcCtD
Dabrafenib—Abdominal pain—Methotrexate—esophageal cancer	0.000148	0.00121	CcSEcCtD
Dabrafenib—Body temperature increased—Methotrexate—esophageal cancer	0.000148	0.00121	CcSEcCtD
Dabrafenib—ABCB1—lymph node—esophageal cancer	0.000146	0.00471	CbGeAlD
Dabrafenib—Hypersensitivity—Methotrexate—esophageal cancer	0.000138	0.00113	CcSEcCtD
Dabrafenib—Asthenia—Methotrexate—esophageal cancer	0.000135	0.0011	CcSEcCtD
Dabrafenib—Pruritus—Methotrexate—esophageal cancer	0.000133	0.00108	CcSEcCtD
Dabrafenib—Diarrhoea—Methotrexate—esophageal cancer	0.000128	0.00105	CcSEcCtD
Dabrafenib—Dizziness—Methotrexate—esophageal cancer	0.000124	0.00101	CcSEcCtD
Dabrafenib—Vomiting—Methotrexate—esophageal cancer	0.000119	0.000972	CcSEcCtD
Dabrafenib—Rash—Methotrexate—esophageal cancer	0.000118	0.000964	CcSEcCtD
Dabrafenib—Dermatitis—Methotrexate—esophageal cancer	0.000118	0.000963	CcSEcCtD
Dabrafenib—Headache—Methotrexate—esophageal cancer	0.000118	0.000958	CcSEcCtD
Dabrafenib—Nausea—Methotrexate—esophageal cancer	0.000111	0.000908	CcSEcCtD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.18e-05	0.00012	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GNG7—esophageal cancer	2.17e-05	0.000119	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.17e-05	0.000119	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	2.16e-05	0.000118	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CYP2A6—esophageal cancer	2.16e-05	0.000118	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.15e-05	0.000118	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HIF1A—esophageal cancer	2.15e-05	0.000118	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—ERBB2—esophageal cancer	2.14e-05	0.000117	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PLCE1—esophageal cancer	2.14e-05	0.000117	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ADH7—esophageal cancer	2.14e-05	0.000117	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ABCB1—esophageal cancer	2.13e-05	0.000117	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALDH2—esophageal cancer	2.13e-05	0.000117	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	2.11e-05	0.000116	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.11e-05	0.000116	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—EGFR—esophageal cancer	2.08e-05	0.000114	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ENO1—esophageal cancer	2.05e-05	0.000112	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS1—esophageal cancer	2.05e-05	0.000112	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.04e-05	0.000112	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—XIAP—esophageal cancer	2.04e-05	0.000112	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ABL1—esophageal cancer	2.03e-05	0.000111	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—PIK3CA—esophageal cancer	2.03e-05	0.000111	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTT1—esophageal cancer	2.02e-05	0.000111	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PSME1—esophageal cancer	2.02e-05	0.000111	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PSME2—esophageal cancer	2.02e-05	0.000111	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CA2—esophageal cancer	2e-05	0.00011	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYP2A6—esophageal cancer	2e-05	0.00011	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—PIK3CA—esophageal cancer	1.99e-05	0.000109	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NOS2—esophageal cancer	1.95e-05	0.000107	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—BCL2—esophageal cancer	1.95e-05	0.000107	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFBR2—esophageal cancer	1.94e-05	0.000107	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NOTCH1—esophageal cancer	1.93e-05	0.000106	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CTNNA1—esophageal cancer	1.93e-05	0.000106	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFBR2—esophageal cancer	1.92e-05	0.000105	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL2—esophageal cancer	1.92e-05	0.000105	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—PIK3CA—esophageal cancer	1.91e-05	0.000105	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	1.91e-05	0.000105	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ENO1—esophageal cancer	1.89e-05	0.000104	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS1—esophageal cancer	1.89e-05	0.000104	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.89e-05	0.000104	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—ERBB2—esophageal cancer	1.89e-05	0.000104	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ADH1B—esophageal cancer	1.87e-05	0.000103	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PSME2—esophageal cancer	1.87e-05	0.000102	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PSME1—esophageal cancer	1.87e-05	0.000102	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ADH7—esophageal cancer	1.86e-05	0.000102	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PLCE1—esophageal cancer	1.86e-05	0.000102	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	1.85e-05	0.000101	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SMAD4—esophageal cancer	1.84e-05	0.000101	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SMAD4—esophageal cancer	1.82e-05	9.97e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—ERBB2—esophageal cancer	1.82e-05	9.96e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PSME1—esophageal cancer	1.79e-05	9.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PSME2—esophageal cancer	1.79e-05	9.82e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TYMP—esophageal cancer	1.79e-05	9.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ANXA1—esophageal cancer	1.78e-05	9.78e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.76e-05	9.66e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	1.76e-05	9.63e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CREBBP—esophageal cancer	1.75e-05	9.63e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP26A1—esophageal cancer	1.74e-05	9.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EP300—esophageal cancer	1.74e-05	9.55e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CYP1B1—esophageal cancer	1.74e-05	9.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SST—esophageal cancer	1.73e-05	9.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—EP300—esophageal cancer	1.71e-05	9.37e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALOX15—esophageal cancer	1.7e-05	9.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOTCH3—esophageal cancer	1.69e-05	9.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GHRL—esophageal cancer	1.69e-05	9.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FBXW7—esophageal cancer	1.66e-05	9.12e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CYP19A1—esophageal cancer	1.64e-05	8.98e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ADH1B—esophageal cancer	1.63e-05	8.95e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTO1—esophageal cancer	1.62e-05	8.88e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TPI1—esophageal cancer	1.62e-05	8.88e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CDKN1A—esophageal cancer	1.62e-05	8.87e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.61e-05	8.85e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYP1B1—esophageal cancer	1.61e-05	8.84e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.6e-05	8.76e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—BLVRB—esophageal cancer	1.59e-05	8.7e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC52A3—esophageal cancer	1.59e-05	8.7e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NOS3—esophageal cancer	1.57e-05	8.62e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TYMP—esophageal cancer	1.56e-05	8.56e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALDOB—esophageal cancer	1.55e-05	8.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CDKN1A—esophageal cancer	1.55e-05	8.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TLR4—esophageal cancer	1.54e-05	8.45e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EP300—esophageal cancer	1.54e-05	8.44e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.53e-05	8.4e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP26A1—esophageal cancer	1.52e-05	8.32e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYP19A1—esophageal cancer	1.51e-05	8.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOTCH2—esophageal cancer	1.51e-05	8.31e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HIF1A—esophageal cancer	1.5e-05	8.25e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.5e-05	8.21e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GAPDH—esophageal cancer	1.49e-05	8.2e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—HMOX1—esophageal cancer	1.49e-05	8.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HIF1A—esophageal cancer	1.49e-05	8.15e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EGFR—esophageal cancer	1.48e-05	8.14e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CRABP1—esophageal cancer	1.48e-05	8.12e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALOX15—esophageal cancer	1.48e-05	8.11e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—ERBB2—esophageal cancer	1.47e-05	8.06e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.46e-05	8.04e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KDR—esophageal cancer	1.44e-05	7.89e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—esophageal cancer	1.44e-05	7.88e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ABCB1—esophageal cancer	1.43e-05	7.86e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CREBBP—esophageal cancer	1.43e-05	7.82e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTO1—esophageal cancer	1.41e-05	7.74e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TPI1—esophageal cancer	1.41e-05	7.74e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GNG7—esophageal cancer	1.41e-05	7.73e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—HMOX1—esophageal cancer	1.38e-05	7.59e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOTCH1—esophageal cancer	1.35e-05	7.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS2—esophageal cancer	1.35e-05	7.42e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALDOB—esophageal cancer	1.35e-05	7.42e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CA1—esophageal cancer	1.35e-05	7.4e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC10A2—esophageal cancer	1.35e-05	7.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFBR2—esophageal cancer	1.34e-05	7.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOTCH1—esophageal cancer	1.34e-05	7.35e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ABCB1—esophageal cancer	1.33e-05	7.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CASP8—esophageal cancer	1.32e-05	7.25e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALDH2—esophageal cancer	1.32e-05	7.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CREBBP—esophageal cancer	1.31e-05	7.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EGFR—esophageal cancer	1.31e-05	7.19e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GAPDH—esophageal cancer	1.3e-05	7.14e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.3e-05	7.13e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CRABP1—esophageal cancer	1.29e-05	7.08e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—NOS3—esophageal cancer	1.28e-05	7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SMAD4—esophageal cancer	1.27e-05	6.98e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—PIK3CA—esophageal cancer	1.26e-05	6.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—EGFR—esophageal cancer	1.26e-05	6.9e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.26e-05	6.89e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CDKN1A—esophageal cancer	1.26e-05	6.89e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTT1—esophageal cancer	1.25e-05	6.89e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP2A6—esophageal cancer	1.24e-05	6.81e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.24e-05	6.78e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CA2—esophageal cancer	1.23e-05	6.77e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CREBBP—esophageal cancer	1.23e-05	6.74e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GNG7—esophageal cancer	1.23e-05	6.73e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—esophageal cancer	1.22e-05	6.71e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CREBBP—esophageal cancer	1.21e-05	6.66e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EP300—esophageal cancer	1.19e-05	6.56e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ENO1—esophageal cancer	1.18e-05	6.45e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS1—esophageal cancer	1.18e-05	6.45e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—esophageal cancer	1.17e-05	6.4e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PSME2—esophageal cancer	1.16e-05	6.36e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PSME1—esophageal cancer	1.16e-05	6.36e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALDH2—esophageal cancer	1.15e-05	6.31e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.15e-05	6.29e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ADH7—esophageal cancer	1.15e-05	6.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PIK3CA—esophageal cancer	1.14e-05	6.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—BCL2—esophageal cancer	1.13e-05	6.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ERBB2—esophageal cancer	1.1e-05	6.04e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOS3—esophageal cancer	1.1e-05	6.04e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTT1—esophageal cancer	1.09e-05	6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PIK3CA—esophageal cancer	1.09e-05	5.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS3—esophageal cancer	1.09e-05	5.96e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.08e-05	5.94e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.08e-05	5.93e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—esophageal cancer	1.04e-05	5.71e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HIF1A—esophageal cancer	1.04e-05	5.71e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ERBB2—esophageal cancer	1.03e-05	5.65e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ENO1—esophageal cancer	1.02e-05	5.62e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS1—esophageal cancer	1.02e-05	5.62e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.02e-05	5.62e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EGFR—esophageal cancer	1.02e-05	5.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ERBB2—esophageal cancer	1.02e-05	5.58e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.01e-05	5.55e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PSME2—esophageal cancer	1.01e-05	5.54e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PSME1—esophageal cancer	1.01e-05	5.54e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ADH1B—esophageal cancer	1e-05	5.52e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP1B1—esophageal cancer	1e-05	5.49e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KDR—esophageal cancer	9.95e-06	5.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—esophageal cancer	9.94e-06	5.45e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—EP300—esophageal cancer	9.71e-06	5.33e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TYMP—esophageal cancer	9.6e-06	5.27e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CREBBP—esophageal cancer	9.58e-06	5.25e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1A—esophageal cancer	9.41e-06	5.16e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP19A1—esophageal cancer	9.4e-06	5.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOTCH1—esophageal cancer	9.37e-06	5.14e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	9.34e-06	5.13e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALOX15—esophageal cancer	9.1e-06	5e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCND1—esophageal cancer	9.09e-06	4.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EP300—esophageal cancer	8.95e-06	4.91e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CREBBP—esophageal cancer	8.87e-06	4.87e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CA—esophageal cancer	8.84e-06	4.85e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1A—esophageal cancer	8.79e-06	4.83e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP1B1—esophageal cancer	8.71e-06	4.78e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1A—esophageal cancer	8.69e-06	4.77e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TPI1—esophageal cancer	8.69e-06	4.77e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTO1—esophageal cancer	8.69e-06	4.77e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HMOX1—esophageal cancer	8.58e-06	4.71e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NOS3—esophageal cancer	8.57e-06	4.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CREBBP—esophageal cancer	8.5e-06	4.66e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	8.41e-06	4.62e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EP300—esophageal cancer	8.37e-06	4.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—esophageal cancer	8.35e-06	4.58e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALDOB—esophageal cancer	8.33e-06	4.57e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EP300—esophageal cancer	8.27e-06	4.54e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ABCB1—esophageal cancer	8.23e-06	4.52e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP19A1—esophageal cancer	8.19e-06	4.49e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GAPDH—esophageal cancer	8.02e-06	4.4e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CRABP1—esophageal cancer	7.94e-06	4.36e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NOS3—esophageal cancer	7.94e-06	4.36e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—esophageal cancer	7.84e-06	4.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—esophageal cancer	7.63e-06	4.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOS3—esophageal cancer	7.61e-06	4.18e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GNG7—esophageal cancer	7.56e-06	4.15e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HMOX1—esophageal cancer	7.47e-06	4.1e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—esophageal cancer	7.29e-06	4e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—esophageal cancer	7.26e-06	3.98e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CA—esophageal cancer	7.25e-06	3.98e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—esophageal cancer	7.2e-06	3.95e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CA—esophageal cancer	7.18e-06	3.94e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—esophageal cancer	7.13e-06	3.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ERBB2—esophageal cancer	7.12e-06	3.91e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALDH2—esophageal cancer	7.08e-06	3.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—esophageal cancer	7.05e-06	3.87e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTT1—esophageal cancer	6.73e-06	3.7e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	6.66e-06	3.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CA—esophageal cancer	6.62e-06	3.63e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—EP300—esophageal cancer	6.52e-06	3.58e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS1—esophageal cancer	6.31e-06	3.46e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ENO1—esophageal cancer	6.31e-06	3.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCND1—esophageal cancer	6.29e-06	3.45e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.22e-06	3.42e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PSME2—esophageal cancer	6.22e-06	3.41e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PSME1—esophageal cancer	6.22e-06	3.41e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CA—esophageal cancer	6.19e-06	3.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CA—esophageal cancer	6.12e-06	3.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1A—esophageal cancer	6.08e-06	3.34e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—EP300—esophageal cancer	6.04e-06	3.31e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—esophageal cancer	5.99e-06	3.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EP300—esophageal cancer	5.79e-06	3.18e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CREBBP—esophageal cancer	5.5e-06	3.02e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	5.37e-06	2.94e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	5.05e-06	2.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—esophageal cancer	5.04e-06	2.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—esophageal cancer	4.93e-06	2.71e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NOS3—esophageal cancer	4.93e-06	2.7e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CA—esophageal cancer	4.82e-06	2.65e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CREBBP—esophageal cancer	4.79e-06	2.63e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HMOX1—esophageal cancer	4.6e-06	2.53e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—esophageal cancer	4.51e-06	2.47e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CA—esophageal cancer	4.47e-06	2.45e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCB1—esophageal cancer	4.42e-06	2.43e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NOS3—esophageal cancer	4.29e-06	2.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CA—esophageal cancer	4.28e-06	2.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—esophageal cancer	4.14e-06	2.27e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—esophageal cancer	3.93e-06	2.15e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—EP300—esophageal cancer	3.75e-06	2.06e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—EP300—esophageal cancer	3.26e-06	1.79e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.95e-06	1.62e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CA—esophageal cancer	2.77e-06	1.52e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NOS3—esophageal cancer	2.64e-06	1.45e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.42e-06	1.33e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CA—esophageal cancer	2.42e-06	1.33e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—EP300—esophageal cancer	2.01e-06	1.1e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.49e-06	8.17e-06	CbGpPWpGaD
